Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Steven De Beukelaer"'
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Autor:
M Dvorkin, Jean Bourhis, Antonio Rueda, Amanda Psyrri, József Lövey, Robert L. Ferris, Holger Thurm, Steven De Beukelaer, Mohammad Abdul Razaq, Kevin J. Harrington, Chaosu Hu, Lara Dunn, Jin-Ching Lin, Ezra E.W. Cohen, Makoto Tahara, Robert I. Haddad, Nancy Y. Lee, Dmitri Pavlov, Peter Mu Hsin Chang, Maria Margarida Teixeira, Jerome Chamois
Publikováno v:
The Lancet Oncology. 22:450-462
Summary Background Chemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes f
Autor:
Jozsef Lövey, Ezra E.W. Cohen, Steven De Beukelaer, Makoto Tahara, Kevin J. Harrington, Jean Bourhis, Robert L. Ferris, Chaosu Hu, Holger Thurm, Mohammad Abdul Razaq, Amanda Psyrri, Lara Dunn, Robert I. Haddad, Antonio Rueda, Nancy Y. Lee, Dmitri Pavlov, Peter Mu Hsin Chang, Mikhail Vladimirovich Dvorkin, Maria Margarida Teixeira, Jerome Chamois, Jin-Ching Lin
Publikováno v:
SSRN Electronic Journal.
Background: Chemoradiotherapy (CRT) is the current standard of care for unresected locally advanced squamous cell carcinoma of the head of neck (LA SCCHN). We report the results of avelumab (anti–PD-L1) combined with CRT in LA SCCHN (JAVELIN Head a